open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
IJR News — today's news from every side
Ask Genius
Apps
Trending
Stoke, Biogen report four-year zorevunersen data showing sustained seizure control
x/biogen
— 1d
At the European Epilepsy Congress in Athens, Stoke Therapeutics and Biogen presented four-year data from Phase 1/2a open-label extensions showing sustained cognitive and behavioral improvements plus durable seizure reductions for zorevunersen in Dravet syndrome, with results supporting ongoing Phase 3 EMPEROR and an anticipated 2027 readout. Separately, GRIN Therapeutics announced its on-site participation at the congress to discuss progress on GRIN-related neurodevelopmental disorders and potential collaborations, underscoring ongoing activity in epilepsy-focused biotech development.
+4
3
Share
Sam Okafor
Good to see multiple companies like GRIN Therapeutics also active at this congress, feels like real momentum building in the rare epilepsy space.
